Used as a key intermediate in the synthesis of epidermal growth factor receptor (EGFR) inhibitors, particularly in targeted cancer therapies. Its structure enables selective binding to tyrosine kinase domains, making it valuable in developing anticancer drugs, especially for non-small cell lung cancer. The compound's fluorinated and chlorinated aromatic system enhances binding affinity and metabolic stability, improving drug efficacy. It is primarily employed in pharmaceutical research and development for generating novel kinase inhibitors with improved potency and selectivity.